COVID-19 mass testing in adult social care in England

Siyu Chen[1†], Richard Creswell[2†], Rachel Hounsell[3,6†], Liberty Cantrell[4], Sumali Bajaj[5], Prabin Dahal[3,6], Lok Hei Tsui[5], Olumide Kolade[7], Ma'ayan Amswych[8], Reshania Naidoo[3,8], Tom Fowler[7], Susan Hopkins[7,9], Kasia Stepniewska[6], Merryn Voysey[4], Lisa White[5], Rima Shretta[3], Ben Lambert[10*] on behalf of the EY-Oxford Health Analytics Consortium[**]

[1]High Meadows Environmental Institute, Princeton University, USA

[2]Department of Computer Science, University of Oxford, UK

[3]Nuffield Department of Medicine, University of Oxford, UK

[4]Department of Paediatrics, University of Oxford, UK

[5]Department of Biology, University of Oxford, UK

[6]Centre for Tropical Medicine and Global Health, University of Oxford, UK

[7]UK Health Security Agency, London, UK

[8]Ernst & Young LLP, London, UK

[9]NIHR Health Protection Research Unit in Healthcare associated infections and Antimicrobial Use, University of Oxford, UK

[10]Department of Statistics, University of Oxford, UK

[†] These authors contributed equally.

*Corresponding author: ben.lambert@stats.ox.ac.uk

**EY-Oxford Health Analytics Consortium membership list (as listed in a separate file)

Ricardo Aguas, Ma'ayan Amswych, Billie Andersen-Waine, Sumali Bajaj, Kweku Bimpong, Adam Bodley, Liberty Cantrell, Siyu Chen, Richard Creswell, Prabin Dahal, Sophie Dickinson, Sabine Dittrich, Tracy Evans, Angus Ferguson-Lewis, Caroline Franco, Bo Gao, Rachel Hounsell, Muhammad Kasim, Claire Keene, Ben Lambert, Umar Mahmood, Melinda Mills, Ainura Moldokmatova, Sassy Molyneux, Reshania Naidoo, Randolph Ngwafor Anye, Jared Norman, Wirichada Pan-Ngum, Sarah Pinto-Duschinsky, Sunil Pokharel, Anastasiia Polner, Katarzyna Przybylska, Emily Rowe, Sompob Saralamba, Rima Shretta, Sheetal Silal, Kasia Stepniewska, Joseph Tsui, Merryn Voysey, Marta Wanat, Lisa White, Gulsen Yenidogan

Abstract

Introduction

We retrospectively evaluated the impact of COVID-19 testing among residents and staff in adult social care homes in England.

Methods

We obtained 80 million reported polymerase chain reaction (PCR) and lateral flow device (LFD) test results, from 14,805 care homes (residents and staff) in England, conducted between October 2020 and March 2022. These testing data were then linked to care home characteristics, test costs and 24,500 COVID-19-related deaths of residents. We decomposed the mechanism of outbreak mitigation into outbreak discovery and outbreak control and used Poisson regressions to investigate how reported testing intensity was associated with the size of outbreak discovered and to uncover its association with outbreak control. We used negative binomial regressions to determine the factors influencing COVID-19-related deaths subsequent to outbreaks. We performed a cost-effectiveness analysis of the impact of testing for preventing COVID-19-related deaths of residents.

Results

Reported testing intensity generally reflected changes in testing policy over time, although there was considerable heterogeneity among care homes. Client type was the strongest determinant of whether COVID-19-related deaths in residents occurred subsequent to testing positive. Higher staff-to-resident ratios were associated with larger outbreak sizes but rapid outbreak control and a decreased risk of COVID-19-related deaths. Assuming our regression estimates represent causal effects, care home testing in England was cost effective at preventing COVID-19-related deaths among residents during the pandemic and approximately 3·5-times more cost effective prior to the vaccine rollout.

Conclusions

PCR and LFD testing was likely an impactful intervention for detecting and controlling COVID-19 outbreaks in care homes in England and cost effective for preventing COVID-19-related deaths among residents. In future pandemics, testing must be prioritised for care homes, especially if severe illness and death particularly affects older people or individuals with characteristics similar to care home residents, and an efficacious vaccine is unavailable.

Key Messages

Evidence before this study

Mass diagnostic testing plays a key role in any pandemic response. COVID-19 testing in the adult social care sector in England was implemented by NHS Test and Trace (later the UK Health Security Agency, UKHSA). Prior to the large-scale evaluation we report here, a pilot testing evaluation programme had been conducted in Liverpool.

Added value of this study

This study represents the first large-scale evaluation of England's COVID-19 testing programme in adult social care homes. It encompasses data from residents and staff from 14,805 adult social care homes in England. Our findings show that testing was an important and useful public health intervention that had a considerable impact. It was also cost effective at preventing COVID-19-related deaths in adult social care home residents.

Implications of all the available evidence

Our study has implications for the development of testing policies in adult social care homes in any future pandemic, particularly if it involves a respiratory disease similar to COVID-19. We found that while testing was a crucial public health intervention in adult social care homes, there were also large heterogeneities seen among care homes. Policymakers thus need to consider whether a one-size-fits-all policy for care home testing is the most effective approach to take in the face of any future pandemic.

Introduction

Adult social care homes were hit hard by the COVID-19 pandemic, both in the UK and internationally, experiencing high levels of COVID-19-related mortality (and excess mortality) among residents and staff.[1-7] This was in part due to the old age, frailty, and comorbidities of care home residents, who typically have multiple needs and require a range of frequent close care and support interactions.[8,9] It was also partly due to the close contact among residents and between residents and staff, with staff usually living in the wider community, frequently working in more than one care home, and potentially carrying infections as they moved between care homes, resulting in rapid transmission and subsequent severe outbreaks.[10]

In March 2020, England's Department of Health and Social Care (DHSC) established a large-scale testing programme to identify individuals infected with SARS-CoV-2, with one of the first established testing services being within the adult social care sector.[11] England's COVID-19 testing policy within adult social care (which encompasses care homes) had several intended objectives, including to control the spread of infection[12] and consequently reduce hospitalisation and mortality rates. However, the testing policy and its implementation changed several times throughout the course of the COVID-19 pandemic and depending on the availability of tests. For staff testing, routine weekly asymptomatic polymerase chain reaction (PCR) testing was rolled out in July 2020.[13] This was later changed to twice-weekly testing with lateral flow devices (LFDs) in December 2020,[14,15] increasing to three times a week in December 2021 in response to the emergence of the Omicron variant,[16] and further increasing to daily pre-shift LFDs in February 2022.[17] For resident testing, a policy of monthly PCR testing was maintained until February 2022,[13] with increased frequency during outbreaks in care homes (involving both LFD and PCR tests, including for staff) from July

105 2020.[18-20] However, the impacts of this large-scale COVID-19 testing programme and
106 associated policies in social care settings have yet to be evaluated.

107 Studies of the impact of the COVID-19 pandemic on care homes have tended to focus on
108 describing correlations between the characteristics of a care home with infection rates,[21]
109 outbreak magnitudes,[1,7,22,23] or COVID-19-related deaths.[1,24] These studies were generally
110 conducted early on during the pandemic, when COVID-19 tests were extremely scarce, or
111 they included very few care homes. Here, we describe an in-depth analysis of the impact of
112 testing for COVID-19 in adult social care homes, which formed part of a retrospective,
113 independent evaluation of the COVID-19 mass testing programme between October 2020
114 and March 2022 in England, commissioned by the UK Health Security Agency (UKHSA).[11,25]

115 Materials and Methods

116 Data sources

117 As part of a retrospective evaluation of England's COVID-19 testing policy,[11] we had access
118 to mass testing data from care homes, which we later linked to testing cost, mortality, and
119 care home characteristics data. This enabled us to assess the factors associated with the
120 level of testing reported in care homes and probe the mechanisms by which testing affected
121 outbreak discovery and control and COVID-19-related deaths in care homes. Furthermore,
122 we compared the cost effectiveness of counterfactual SARS-CoV-2 testing intensity levels in
123 care homes on resident quality-adjusted life-years (QALYs) gained. We were supplied "Pillar
124 2" testing data for both PCR and LFD tests (Pillar 2 refers to swab testing for SARS-CoV-2 in
125 the general population, through commercial partnerships, either processed in a laboratory
126 or more rapidly via LFDs.[26]) Our analysis period covered 1 October 2020 to 30 March 2022.
127 The testing data were linked to several other datasets, either at the individual care home

level or at the level of the lower-tier local authority (LTLA) encompassing the care homes, including:

- COVID-19-related deaths of care home residents as reported to the Care Quality Commission (CQC), which included both confirmed and suspected COVID-19-related deaths.
- Characteristics of individual care homes obtained from the NHS North of England Care System Support (NECS) Capacity Tracker,[27] including the CQC rating and primary client type severed by the care home (Supplementary Table S17).
- Weekly estimates of COVID-19 community prevalence according to the LTLA within which each care home was situated. These estimates were generated using a causal debiasing methodology,[28] which used high-quality randomised surveillance data of swab-positive results provided via the REACT-1 survey[29] to debias PCR testing data obtained through Pillar 2.
- Weekly vaccination data for staff and residents in individual care homes by dose type (dose 1, dose 2, dose 3, booster, spring 2022 booster, or null).
- Weekly proportions of SARS-CoV-2 lineages by LTLA, downloaded from the Sanger Institute website.[30]
- Mid-2020 estimates of population sizes by region in England, obtained from the publicly accessible Office for National Statistics (ONS) website.[31]
- COVID-19 testing costs derived from the Cost Allocation Project (an unpublished internal project) conducted by UKHSA for the ONS. These testing cost data were primarily sourced from UKHSA general ledgers.

We considered only those care homes actively registered with CQC. To determine this, we downloaded the CQC care directory with filters for each month during the evaluation period and used the unique list of 15,833 care homes as our reference set. Of these, we were able

to match 14,805 care homes with testing data and COVID-19-related deaths data with the various other sources of data; all results reported below are based on this set. More details on data definitions and processing can be found in the Supplementary Materials Sections 2 and 3.

Public Involvement

The concept of public involvement also translated to the results interpretation and translation phases of the research. As part of the evaluation programme, we presented care home providers basic statistic findings to help to encourage familiarity with research concepts and terminology. They described the barriers and motivations of implementing the testing policy, reporting the testing results, and acting on a positive result in practice during the COVID-19 pandemic. We expanded the evaluation scope and refined the research findings to align them better with things that care providers cared about the most. Through these iterative processes, care home providers made high value contributions to both the design and the interpretation of the study, while we retained the rigors of the scientific work.

Methods

We define reported testing intensity over a particular time period, e.g. weekly, of a particular group, e.g. staff or resident counts, in a particular care home as:

$$\text{reported testing intensity} = \frac{\text{reported number of tests}}{\text{population size}}$$

Equation (1)

We assumed that the sole impact of testing on resident deaths in care homes was through its impact on COVID-19 outbreak discovery and outbreak control. By testing staff and residents more frequently at higher intensities, outbreaks (or single, isolated cases) can be

discovered earlier, with the result that initial outbreak sizes upon detection are smaller (Fig. 1A). Once an outbreak has been discovered, higher testing coverages enable cases to be identified earlier and isolated more effectively, resulting in more rapid reductions in onward cases and thus more rapid control (Fig. 1B). Through both mechanisms, higher testing coverages would lead to smaller outbreaks of COVID-19 in care homes and likely a reduction in the number of deaths among residents.

To test this hypothesis, we used Poisson regression models to empirically probe the mechanisms by which changes in testing influenced the number of positive cases. We also used negative binomial regressions to probe the relationship between positive cases and COVID-19-related deaths.

The association between reported testing intensity and the size of outbreaks when discovered

We used Poisson regressions to investigate how testing intensity in both residents and staff influenced outbreak size during the process of "outbreak discovery". We define outbreak discovery as the period when care homes uncovered no positive cases one week but did so in the following week. These regressions took the general form:

$$X_{i,t+1} \sim \text{Poisson}\left(N_{i,t+1}\theta_{ltla[i],t}\exp\left(\alpha + \beta_r T_{i,t}^r + \beta_s T_{i,t}^s + \gamma Z_{i,t}\right)\right)$$

Equation (2)

where $X_{i,t}$ denotes the number of positive tests in care home i and week t, and $N_{i,t}$ denotes the corresponding number of tests conducted; $\theta_{ltla[i],t}$ denotes the estimated COVID-19 prevalence in the LTLA that encompasses care home i; $T_{i,t}^r$ and $T_{i,t}^s$ denote the reported testing intensities in residents and staff, respectively; and $Z_{i,t}$ denotes a vector of additional covariates, including weekly time dummies that account for secular changes in the relationship between tests and positive results over time across England. In what follows,

we group PCR and LFD tests together for either residents or staff, as these regression results tended to be more stable.

The association between reported testing intensity and outbreak control

We used Poisson regressions to investigate how, after positive cases were found within a care home, the response was able to identify (and, if possible, isolate) cases, leading to reductions in the size of the outbreaks in subsequent weeks. We refer to this process as "outbreak control". To do so, we considered only those weeks where the previous week had at least one positive case in either staff or residents. The regressions using these data then took the following form:

$$X_{i,t+1} \sim Poisson(N_{i,t+1} \frac{X_{i,t}}{n_{i,t}} \exp\left(\alpha + \beta_r T_{i,t}^r + \beta_s T_{i,t}^s + \gamma Z_{i,t}\right))$$

Equation (3)

where the variables appearing both here and in Equation (2) have common meanings, while $n_{i,t} > 0$ is the total number of members of care home i at time t (i.e. the sum of residents and staff numbers).

COVID-19-related deaths of residents

We investigated the factors influencing whether positive COVID-19 cases in residents became deaths by considering four-week blocks for aggregating positive results and deaths (which were chosen to overlap by two weeks in the middle, with future deaths depending on the previous cases), to account for the typical delay between a case being detected and death. This is illustrated in Fig. 1C.

The regressions took the form:

$$D_{i,t} \sim NB\left(X_{i,t-1} \exp\left(\alpha + \beta W_{i,t}\right), \kappa\right)$$

Equation (4)

where $NB(\mu, \kappa)$ denotes a negative binomial distribution parameterised to have mean $\mu > 0$ and an overdispersion parameter κ where, as $\kappa \to \infty$, the distribution tends to a Poisson; $D_{i,t} > 0$ denotes the count of COVID-19-related deaths in a given block, t; $X_{i,t-1} > 0$ denotes the positive count in residents only in the previous block; and $W_{i,t}$ represents various covariates that may affect whether positive test results predict deaths.

Deaths under hypothetical testing scenarios

We used the fitted regression models describing outbreak discovery (Equation (2)) and outbreak control (Equation (3)), together with the model for total COVID-19-related deaths among residents (Equation (4)), to estimate the number of such deaths that would occur under counterfactual testing rates of 50%, 75%, 125%, 150%, and 200% of the actual testing volume. This enabled us to assess the impact of increased or decreased rates of testing and how close the testing regimen actually implemented was to a theoretical "optimal" testing regimen. In using our regression results in this way, we assume that our estimates represent causal effects.

Cost-effectiveness analysis

We conducted a cost-effectiveness analysis to evaluate the impact of testing in care homes on mortality rates among residents. We used estimates of deaths averted among residents under hypothetical testing scenarios (50%, 75%, 125%, 150%, and 200% of the actual testing volume, as described above) as inputs. We proportionally adjusted the direct and direct-overhead costs of these hypothetical reduced and increased testing volumes. We used the QALY value for a COVID-19 death to calculate the QALYs gained due to deaths averted under the hypothetical testing scenarios compared with actual testing rates. The evaluation was conducted from the healthcare provider perspective, as the UK government funded all direct costs of testing and treatment for COVID-19. The time horizon of the analysis was consistent with the evaluation period. We also performed a sub-analysis for the two

248 financial years (FY) within the study period: FY21, comprising the six-month period from
249 October 2020 to March 2021; and FY22, comprising the full financial year from April 2021 to
250 March 2022.

251 We present the incremental cost-effectiveness ratio (ICER) for the cost per death averted in
252 residents due to testing and the cost per QALY gained in residents due to testing. Given the
253 short time-horizon of the study, no discounting or adjustment for inflation was conducted.
254 All costs and results were collected and are presented in pound sterling (GBP). More details
255 on our approach, input parameters, and sources can be found in the Supplementary
256 Materials Section 11.

257 Results

258 Characteristics of care homes studied

259 Care homes whose primary clients were older people (47·4%), people with learning
260 disabilities (28·6%), or people with dementia (12·7%) accounted for more than 88% of the
261 organisations in our dataset. A substantial proportion of care homes were residential homes
262 (70·6%) and were CQC-rated "good" (>75%). Care homes whose primary clients had
263 learning, or physical disabilities had, on average, lower numbers of staff per resident
264 compared with care homes serving older people and those with dementia (Supplementary
265 Table S17).

266 Intended and reported PCR and LFD testing intensities

267 Testing policies for the adult social care sector in England evolved throughout our
268 evaluation period (Supplementary Table S1 and Supplementary Materials Section 1).
269 Whereas the reported testing intensities of PCR tests per staff member and per resident
270 remained consistently at or near the guidance levels, the reported testing intensities of LFDs
271 among staff were consistently lower than the intended testing rates (Fig. 2, Supplementary

Table S1). However, there were considerable heterogeneities across different care home types. The median number of reported tests per resident or staff member per week was higher in better CQC-rated care homes, i.e., those rated “outstanding” or “good”, and the level of staff testing was highest in care homes serving older individuals and individuals with dementia (Table S1).

Volumes of tests and associated costs

In total, 227 million LFDs were distributed from October 2020 to March 2022 for the adult social care testing service, representing 11·4% of the total number distributed in England (Supplementary Table S2). There were 41 million PCR tests registered for adult social care through Pillar 2, representing 35·5% of total Pillar 2 PCR tests in England. Care homes comprised the majority (83%) of the testing volume for adult social care. From October 2020 to March 2022, 189·5 million LFDs were distributed for testing in care homes, 9·5% of the total number distributed for England (Supplementary Table S2). There were 33 million PCR tests registered for care homes through Pillar 2, 28·7% of all Pillar 2 PCR tests.

The total financial cost of the adult social care testing service (LFD and Pillar 2 PCR) was estimated to be GBP 4.8 billion, representing 20·6% of England’s total testing spend (Supplementary Table S3). Approximately 50% of these costs were direct costs and 21% were indirect costs; the remainder were overheads. The total financial cost of testing in care homes for the evaluation period was GBP 3·8 billion, representing 16·2% of England’s total testing spend and 78·7% of the total financial cost for the adult social care testing service (Supplementary Table S3). The average unit cost in the adult social care testing service for an LFD and a PCR test was GBP 6·38 and 78·30, respectively.

Key drivers of changes in reported testing intensity

Only some testing policy changes were associated with changes in reported testing intensities among staff. The introduction in December 2020 of twice-weekly asymptomatic LFD testing among staff in care homes was associated with an average increase in reported LFD testing intensity of 0·10 tests per staff member per week (95% confidence interval (CI), 0·06–0·15) (Table 1). The move to daily LFD testing in February 2022 was also associated with an increase in reported LFD testing intensity of approximately 0·25 tests per staff member per week on average (95% CI, 0·21–0·30) (Table 1). Two other policy changes we considered were not associated with changes in staff testing intensity (Table 1).

Table 1. Regression results for reported testing intensities (PCR and LFD tests) among residents and staff. All sets of regression results represent estimates for linear models fitted using ordinary least squares. The figures in parentheses represent 95% confidence intervals for the coefficient estimates.

		Resident PCR testing intensity	Resident LFD testing intensity	Staff PCR testing intensity	Staff LFD testing intensity
Outbreak size	Average number of positive results per care home member in the previous week (including staff and residents)	0·293*** (0·273, 0·314)	0·141*** (0·128, 0·153)	-1·893*** (-1·946, -1·840)	-0·153*** (-0·226, -0·079)
CQC rating	Inadequate (baseline)				
	Requires improvement	0·013*** (0·006, 0·020)	0·003 (-0·001, 0·008)	0·016* (-0·003, 0·034)	0·038*** (0·012, 0·063)
	Good	0·017*** (0·010, 0·023)	0·007*** (0·002, 0·011)	0·028*** (0·010, 0·046)	0·060*** (0·035, 0·084)
	Outstanding	0·030*** (0·022, 0·038)	0·015*** (0·010, 0·020)	0·042*** (0·021, 0·063)	0·100*** (0·071, 0·130)

	No record		0·009 (-0·007, 0·025)	0·001 (-0·009, 0·011)	0·035* (-0·007, 0·076)	0·044 (-0·014, 0·101)
Primary clients	Older individuals (≥65 years)	No (baseline)				
		Yes	0·005*** (0·002, 0·008)	-0·010*** (-0·013, -0·008)	0·004 (-0·005, 0·012)	0·020*** (0·008, 0·032)
	Individuals with dementia	No (baseline)				
		Yes	0·002 (-0·002, 0·007)	-0·010*** (-0·013, -0·008)	0·004 (-0·007, 0·015)	0·015** (0·0003, 0·030)
	Individuals with learning disabilities	No (baseline)				
		Yes	-0·030*** (-0·033, -0·026)	0·005*** (0·003, 0·007)	0·013*** (0·004, 0·022)	0·039*** (0·027, 0·052)
Local proportion of VOC	Alpha (baseline)					
	Delta		0·025** (0·001, 0·050)	-0·008 (-0·024, 0·007)	-0·043 (-0·106, 0·021)	0·001 (-0·088, 0·089)
	Omicron		0·010 (-0·012, 0·031)	-0·001 (-0·015, 0·012)	0·035 (-0·021, 0·091)	-0·002 (-0·080, 0·076)
Care home size	Number of care workers per resident (staff-to-resident ratio)		0·010*** (0·009, 0·012)	-0·001* (-0·002, 0·0001)	-0·029*** (-0·034, -0·024)	-0·037*** (-0·044, -0·030)
	Fraction of agency workers		-0·015*** (-0·020, -0·011)	-0·001 (-0·004, 0·002)	0·030*** (0·018, 0·042)	0·022** (0·005, 0·038)
	Total resident count		0·0004***	-0·0001***	-0·001***	-0·001***

			(0·0003, 0·0005)	(-0·0002, -0·0001)	(-0·001, -0.0004)	(-0·001, -0·0005)
Care home type	Community care home	No (baseline)				
		Yes	0·004 (-0·001, 0·009)	0·005*** (0·001, 0·008)	0·006 (-0·008, 0·019)	-0·007 (-0·025, 0·012)
	Acute care home	No (baseline)				
		Yes	-0·001 (-0·079, 0·077)	-0·019 (-0·067, 0·030)	-0·109 (-0·311, 0·092)	-0·178 (-0·458, 0·102)
	Nursing home	No (baseline)				
		Yes	0·003** (0·0003, 0·005)	-0·002*** (-0·004, -0·001)	0·023*** (0·016, 0·029)	0·015*** (0·006, 0·024)
	Independent organisation	No (baseline)				
		Yes	-0·081*** (-0·118, -0·044)	-0·018 (-0·042, 0·005)	0·208*** (0·112, 0·303)	0·399*** (0·267, 0·532)
Testing policy changes	Twice-weekly LFD testing in staff since 23 December 2020					0·104*** (0·062, 0·146)
	Regular asymptomatic testing since 13 April 2021				-0·029 (-0·082, 0·023)	0·029 (-0·013, 0·070)
	Thrice-weekly LFD testing in staff since 15 December 2021					0·014 (-0·042, 0·071)
	Daily LFD testing in staff since 16 February 2022					0·251*** (0·205, 0·296)
Testing intensity	Residents' PCR	(lag=1)	0·043*** (0·041, 0·045)	0·008*** (0·007, 0·009)	0·568*** (0·566, 0·570)	0·144*** (0·142, 0·147)

		(lag=2)	0·053*** (0·051, 0·055)		0·219*** (0·217, 0·221)	
		(lag=1)	0·041*** (0·039, 0·043)		0·103*** (0·101, 0·106)	
		(lag=2)	0·283*** (0·281, 0·285)		0·062*** (0·060, 0·064)	
		(lag=5)	0·092*** (0·090, 0·094)		0·035*** (0·033, 0·037)	
	Residents' LFD	(lag=1)	0·046*** (0·043, 0.048)	0·442*** (0·440, 0·444)	-0·038*** (-0·039, -0·037)	0·538*** (0·536, 0·540)
		(lag=2)		0·119*** (0·117, 0·122)		0·117*** (0·115, 0·120)
		(lag=3)		0·047*** (0·044, 0·049)		0·099*** (0·097, 0·102)
		(lag=4)		0·067*** (0·065, 0·069)		-0·036*** (-0·038, -0·034)
		(lag=5)		0·075*** (0·073, 0·077)		0·162*** (0·160, 0·164)
	Staff PCR	(lag=1)	0·042*** (0·042, 0·043)	-0·003*** (-0·003, -0·003)	0·093*** (0·087, 0·098)	0·021*** (0·014, 0·029)
	Staff LFD	(lag=1)	-0·008*** (-0·009, -0·008)	0·003*** (0·003, 0·003)	-0·006* (-0·013, 0·0004)	0·057*** (0·047, 0·066)
COVID-19 in the community	Community infection prevalence		0·900*** (0·676, 1·125)	-0·136* (-0·276, 0·004)	-0·213 (-0·793, 0·367)	1·132*** (0·325, 1·939)
	Local proportion of variant of concern	Alpha (baseline)				
		Delta	0·025** (0·001, 0·050)	-0·008 (-0·024, 0·007)	-0·043 (-0·106, 0·021)	0·001 (-0·088, 0·089)

		Omicron	0·010 (-0·012, 0·031)	-0·001 (-0·015, 0·012)	0·035 (-0·021, 0·091)	-0·002 (-0·080, 0·076)
Constant			0·041*** (0·030, 0·053)	0·005 (-0·002, 0·012)	0·162*** (0·133, 0·192)	-0·173*** (-0·214, -0·133)

Note: *p<0·1; **p<0·05; ***p<0·01

Care home resident testing tended to increase if positive cases were found. In several care homes, reported testing intensities appeared to change rapidly, coinciding with or following increases in testing positivity (Supplementary Fig. S3, Supplementary Table S1, and Supplementary Materials Section 1); this likely indicated a shift to outbreak testing, a policy introduced in February 2021 aimed at controlling outbreaks once they were discovered. (Here, an outbreak was defined as two or more positive (or clinically suspected), linked cases that occurred in the same setting within a 14-day period.) This observation was supported by regression analyses showing that higher numbers of positive results per care home member (including residents and staff members) were associated with increased reported testing intensities in residents the following week (Table 2).

Table 2. Regression results for determinants of outbreak size during outbreak discovery and outbreak control and for resident COVID-19-related deaths. The outbreak discovery and control model results correspond to generalised linear models estimated using a Poisson likelihood and a log-link function with an offset term. The resident COVID-19-related mortality model results correspond to generalised linear models using a negative binomial likelihood and a log-link function with an offset term as described in the Methods section. Coefficients and 95% confidence intervals are shown on the exponentiated scale when applicable. Estimates of the weekly time dummies and the COVID-19 prevalence effects are both suppressed for readability.

Category	Variable	Outbreak discovery		Outbreak control		Resident mortality	
		Resident PCR + LFD positive counts	Staff PCR + LFD positive counts	Resident PCR + LFD	Staff PCR + LFD positive counts	Total resident COVID-19-related deaths	Confirmed resident COVID-19-related deaths

					positive counts			
Testing intensity	log (0.1 + test intensity in residents (lag=1))		0·926*** (0·916, 0·936)	0·999 (0·994, 1·005)	0·675*** (0·669, 0·681)	0·894*** (0·889, 0·898)		
	log (0.1 + test intensity in staff (lag=1))		0·745*** (0·736, 0·755)	0·662*** (0·655, 0·668)	0·729*** (0·721, 0·738)	0·488*** (0·481, 0·495)		
Infections in care home	Number of positive results in residents						0·997** (0·995, 1·000)	0·998 (0·996, 1·001)
CQC rating	Inadequate (baseline)							
	Requires improvement		0·990 (0·925, 1·056)	0·998 (0·952, 1·044)	0·971 (0·930, 1·012)	0·917*** (0·881, 0·953)	1·061 (0·894, 1·228)	1·170* (0·988, 1·353)
	Good		0·904*** (0·840, 0·967)	0·948** (0·904, 0·993)	0·959** (0·919, 0·999)	0·913*** (0·878, 0·948)	1·043 (0·881, 1·204)	1·155 (0·978, 1·332)
	Outstanding		0·784*** (0·707, 0·861)	0·857*** (0·807, 0·907)	0·907*** (0·861, 0·953)	0·894*** (0·856, 0·932)	1·005 (0·815, 1·195)	1·121 (0·914, 1·327)
	No record		0·876* (0·732, 1·020)	0·935 (0·843, 1·028)	0·962 (0·873, 1·051)	0·954 (0·888, 1·020)	1·086 (0·721, 1·451)	1·261 (0·874, 1·648)
Primary clients	Older individuals (≥65 years)	No (baseline)						
		Yes	1·196*** (1·159, 1·233)	0·888*** (0·868, 0·909)	1·318*** (1·295, 1·342)	1·049*** (1·033, 1·066)	2·200*** (2·004, 2·395)	2·382*** (2·168, 2·597)
	Individuals with dementia	No (baseline)						
		Yes	1·251*** (1·210, 1·292)	0·929*** (0·905, 0·952)	1·303*** (1·278, 1·328)	1·056*** (1·038, 1·074)	2·208*** (2·009, 2·408)	2·336*** (2·118, 2·555)
	Individuals with learning disabilities	No (baseline)						
		Yes	1·246*** (1·202, 1·290)	1·199*** (1·176, 1·222)	0·962** (0·931, 0·992)	0·916*** (0·896, 0·936)	0·254***(-0·003, 0·510)	0·278*** (0·001, 0·555)
Local proportion of variant of concern	Alpha (baseline)							
	Delta		1·285 (0·698, 1·872)	0·999 (0·743, 1·256)	0·507** (-0·116, 1·131)	0·455*** (-0·017, 0·928)	4·367 (1·726, 7·009)	5·957 (3·198, 8·716)
	Omicron		1·350*** (1·197, 1·504)	1·319*** (1·223, 1·414)	0·936* (0·864, 1·007)	1·095*** (1·041, 1·149)	0·871 (0·372, 1·371)	0·861 (0·305, 1·416)

Care home size	Care workers per resident (staff-to-resident ratio)		1·037*** (1·012, 1·063)	1·031*** (1·017, 1·045)	0·699*** (0·683, 0·715)	0·568*** (0·556, 0·580)	0·904*** (0·849, 0·959)	0·900*** (0·841, 0·959)
	Fraction of agency workers		1·077*** (1·042, 1·112)	1·071*** (1·040, 1·101)	1·010 (0·982, 1·038)	0·959*** (0·934, 0·984)	1·137** (1·038, 1·236)	1·134** (1·028, 1·240)
	Total resident count		0·981*** (0·980, 0·982)	0·980*** (0·980, 0·981)	1·003*** (1·003, 1·003)	1·005*** (1·004, 1·005)	0·999 (0·996, 1·002)	0·999 (0·996, 1·003)
Care home type	Community care home	No (baseline)						
		Yes	0·983 (0·930, 1·036)	0·937*** (0·909, 0·966)	1·022 (0·993, 1·052)	1·026*** (1·007, 1·046)	0·858** (0·725, 0·991)	0·862** (0·720, 1·003)
	Acute care home	No (baseline)						
		Yes	2·233** (1·491, 2·975)	1·308 (0·858, 1·759)	1·103 (0·559, 1·647)	0·870 (0·420, 1·320)	Note1	Note1
	Nursing home	No (baseline)						
		Yes	0·915*** (0·894, 0.936)	0·939*** (0·926, 0·952)	0·935*** (0·923, 0·947)	1·040*** (1·030, 1·049)	1·247*** (1·202, 1·292)	1·235*** (1·187, 1·283)
	Independent organisation	No (baseline)						
		Yes	1·036 (0·607, 1·465)	1·070 (0·889, 1·251)	1·089 (0·895, 1·282)	1·003 (0·912, 1·094)	1·847* (1·140, 2·555)	1·804 (1·055, 2·552)
Care home vaccination coverage	Average number of all vaccine doses per resident		0·990*** (0·986, 0·994)	1·001*** (1·000, 1·001)	0·985*** (0·982, 0·987)	0·999* (0·998, 1·000)	0·991 (0·979, 1·003)	0·994 (0·982, 1·006)
	Average number of all vaccine doses per staff		0·993*** (0·990, 0·996)	0·988*** (0·986, 0·990)	0·994*** (0·992, 0·995)	1·00 (0·999, 1·001)		
Constant			7·922*** (7·777, 8·066)	13·611*** (13·527, 13·695)	0·391*** (0·241, 0·541)	0·458*** (0·337, 0·580)	0·025*** (-0·422, 0·473)	0·020*** (-0·452, 0·492)

Note:
[1] Estimates of risk of COVID-19-related deaths in acute care homes were dropped from the output as they had extremely high uncertainty reflecting the low numbers of such care homes in our dataset.
[2] *p<0·1; **p<0·05; ***p<0·01

Key drivers of outbreak discovery and control in care homes

Higher reported testing intensities among staff and residents were associated with smaller outbreak sizes before outbreaks were detected and while outbreaks were forming,

340 suggesting earlier outbreak discovery and more rapid outbreak control. In our model, the
341 number of positive cases of residents and staff uncovered during outbreak discovery was
342 0·67% (95% CI, 0·57–0·76) and 2·53% (95% CI, 2·42–2·63) lower, respectively, if the testing
343 intensity (including PCR and LFDs) among staff increases 10% (Table 2). The number of
344 positive cases among staff uncovered during outbreak control was 3·36% (95% CI, 3·28–
345 3·36) lower if the testing intensity (including PCR and LFD tests) among staff increases 10%,
346 while the corresponding figure in residents was higher, at 6·05% (95% CI, 5·34–6·17) (Table
347 2).

348 Nursing and care homes with better CQC ratings experienced smaller outbreaks when
349 initially uncovered, that were more rapidly controlled, compared with homes with a lower
350 CQC rating. Outbreaks uncovered among residents in care homes with an "outstanding"
351 CQC rating were, on average, 21·6% (95% CI, 13·9–29·3) smaller than those uncovered in
352 care homes rated "inadequate" by CQC; the corresponding figure for staff outbreaks was
353 14·3% (95% CI, 9·3–19·3) (Table 2). During the outbreak control phase, care homes rated
354 "outstanding" had an average 9·3% (95% CI, 4·7–13·9) reduction in weekly numbers of
355 positive cases among residents vs "inadequate" care homes; the corresponding figure for
356 positive cases among staff in homes rated "outstanding" was 10·6% (95% CI, 6·8–14·4)
357 (Table 2).

358 The number of positive cases discovered among residents of nursing care homes during
359 outbreak discovery was 8·5% (95% CI, 6·4–10·6) lower compared with non-nursing care
360 homes, while the corresponding number was 6·1% (95% CI, 4·8–7·4) among staff (Table 2).
361 Once an outbreak occurred, it was brought under control more rapidly among residents in
362 nursing homes compared with care homes supporting other types of residential clients;
363 however, the same was not true among staff (Table 2).

Large care homes tended to have smaller outbreaks when they were initially uncovered but they were more difficult to control once detected. If the total resident count increased by one member, the number of positive cases among residents and staff in discovered outbreaks was associated with a decrease of 1·9% (95% CI, 1·8–2·0) and 2·0% (95% CI, 1·9–2·1), respectively (Table 2). However, during an outbreak, a one-unit increase in the number of residents was associated with a reduction in the rate of outbreak control by 0·3% and 0·5% among residents and staff, respectively (Table 2).

Variants of concern were associated with initial outbreak size and the ability of care homes to control outbreaks. During the Omicron variant phase, outbreaks tended to be larger when initially uncovered compared with the Alpha variant phase. Positive cases uncovered among residents during outbreak discovery were on average 35·0% (95% CI, 19·7–50·4) higher during the Omicron variant phase compared with the Alpha variant phase, while the corresponding number was 31·9% (95% CI, 22·3–41·4) among staff (Table 2). The Omicron variant phase tended to be associated with a lower ability of care homes to control outbreaks among staff, and positive cases among staff during the Omicron variant phase were on average 9·5% (95% CI, 4·1–14·9) higher than during the Alpha variant phase (Table 2).

Higher staff-to-resident ratios were associated with larger outbreak sizes when they were uncovered but outbreak control was more rapid thereafter. We estimated that an increase of one additional staff member per resident led to a 3·7% (95% CI, 1·2–6·3) increase in positive cases uncovered among residents and a 3·1% (95% CI, 1·7–4·5) increase among staff (Table 2). However, having more staff per resident was associated with marked reductions in the size of outbreaks subsequent to their discovery in both residents (30·1%; 95% CI, 28·5–31·7) and staff (43·2%; 95% CI, 42·0–44·4).

Larger outbreaks were uncovered among residents in care homes that primarily served individuals with learning disabilities, dementia, or who were older (≥65 years) compared with care homes serving other individuals. Outbreaks in care homes serving older individuals or those with dementia were controlled more slowly than in other types of care homes. The numbers of positive cases uncovered during outbreak discovery among residents in care homes whose primary clients were individuals who were older (≥65 years), had dementia, or had learning disabilities were 19·7% (95% CI, 15·9–23·3), 25·1% (95% CI, 21·0–29·2), and 24·6% (95% CI, 20·2–29·0) higher, respectively, compared with care homes that served different clients. Once detected, outbreaks among residents were brought under control more slowly in care homes whose primary clients were older individuals (≥65 years) (31·8% lower; 95% CI, 29·5–34·2) or who had dementia (30·3% lower; 95% CI, 27·8–32·8) than in care homes with other client groups. Positive cases among residents declined more rapidly after outbreaks were uncovered in care homes whose primary clients were individuals with learning disabilities (3·8%; 95% CI, 0·8–6·9) compared with care homes whose clients did not have learning disabilities (Table 2).

Among staff, the number of positive cases uncovered during outbreak discovery at care homes whose primary clients were older individuals (≥65 years) or those with dementia were 11·2% (95% CI, 9·1–15·9) and 7·1% (95% CI, 4·8–9·5) lower, respectively, compared with care homes whose primary clients were not in these groups. Once outbreaks were detected among staff, they took longer to control in care homes whose primary clients were older individuals (≥65 years) or those with dementia (4·9% (95% CI, 3·3–6·6) and 5·6% (95% CI, 3·8–7·4), respectively). However, outbreak control was 8·4% (95% CI, 6·4–10·4) faster among staff in care homes whose primary clients were individuals with learning disabilities (see also Table 2).

412 **COVID-19-related deaths in care homes and their key drivers**

413 There were 24,500 COVID-19-related deaths of residents, from 14,805 care homes in
414 England, reported to CQC during our evaluation period. The distribution of these deaths
415 indicates large heterogeneities depending on the characteristics of the care homes studied
416 (Supplementary Table S17), suggesting care homes had various risk factors for the likelihood
417 of COVID-19-related deaths. The highest peak in COVID-19-related confirmed and suspected
418 deaths occurred in February 2021, with more than 2000 deaths reported per week (Fig.
419 3(A)). The primary client of a care home was the strongest determinant of the magnitude of
420 COVID-19-related deaths.

421 Supplementary Figure S3 shows that, in those care homes primarily serving older patients
422 (≥65 years) or those with dementia, there was a strong positive association between COVID-
423 19-positive cases and deaths, likely reflecting the underlying (and well-documented)
424 susceptibility of these populations to severe COVID-19 outcomes. Care homes primarily
425 serving individuals with learning disabilities or mental health issues had a lower risk of
426 COVID-19-related deaths. These associations were also reflected in our regression results:
427 the risk of COVID-19-related death (including both confirmed and suspected COVID-19-
428 related death) after testing positive was increased by 120·0% (95% CI, 100·0–140·0) in care
429 homes whose primary clients were older individuals (≥65 years) or were individuals with
430 dementia. In comparison, the risks of COVID-19-related death in care homes whose primary
431 clients were individuals were individuals with learning disabilities were 74·6% (95% CI, 49·0–
432 100·0) lower compared with care homes catering for other types of clients.

433 Nursing homes had a higher rate of COVID-19-related deaths compared with non-nursing
434 homes, with a risk of COVID-19-related death after testing positive that was 24·7% (95% CI,
435 20·2–29·2%) higher (Table 2).

436 Higher staff-to-resident ratios were associated with a reduction in the risk of COVID-19-
437 related deaths. We found that the more care workers per resident, the lower the risk of
438 death from a given positive result. The median number of staff per resident in our dataset
439 was 0·93, and our models indicate that a 25% increase in this ratio would be associated with
440 an approximately 2·4% decrease in the risk of death (95% CI, 1·0–3·8; Table 2).

441 Next, we projected mortality in care homes under counterfactual testing scenarios. We
442 estimated that with a reported testing intensity at 50% of the true levels, deaths among
443 residents of care homes in England would increase by 32,160 (uncertainty interval (UI),
444 27,200–37,740), a 129% increase (UI, 109–152%) in COVID-19-related deaths. With testing
445 at 75%, we estimated an increase of 11,910 (UI, 8500–15,700) and a corresponding
446 percentage change in deaths of 48% (UI, 34–63%). An increase in reported testing intensity
447 of 25% would have reduced deaths by 4680 (UI, 2270–6810), 18% (UI, 9–27%) of overall
448 deaths averted (Fig. 3(B)).

449 Testing in care homes can be considered highly cost effective

450 Table S16 illustrates the cost effectiveness of the actual testing levels using various
451 comparators (see Supplementary Table S15 for the complete set of cost-effectiveness
452 results). We estimated that there was a cost saving of GBP 38,300 per death averted
453 compared with a lower testing rate of 50% of the actual rates. If testing had been conducted
454 at increased levels of 150% and 200% of actual levels, it would have saved GBP 154,100 and
455 210,000, respectively, per additional death that could have been averted. In terms of QALYs,
456 the actual testing had a cost of GBP 5700 per QALY gained compared with a testing rate of
457 50% (of the actual rate), making it a highly cost-effective strategy at both HM Treasury's
458 willingness to pay threshold of GBP 70,000 per QALY gained[32] and the National Institute for
459 Health and Care and Excellence (NICE) threshold of GBP 30,000.[33] If testing had been
460 increased to 150% and 200% of actual levels, it would have cost GBP 22,700 and 31,000,

respectively, for each additional QALY that could have been gained. This suggests that increasing testing of residents and staff to up to double the actual volume may also have been a cost-effective intervention, although the degree of cost effectiveness would have diminished.

While cost effective throughout, testing in care homes was substantially more cost effective prior to the full vaccination rollout. On average, testing in care homes was 3·5-times more cost effective prior to vaccination rollout for the scenarios considered. Fig. 3 illustrates the costs per QALY gained at various testing rates in care homes by financial year. Testing in care homes was cost effective compared with lower levels of testing at 50% and 75% of the actual volume for both FY21 (half year) and FY22 (full year). If testing had been increased to levels of 125%, 150%, or 200% of the actual testing, the additional QALYs that could have been gained would also have been cost effective for FY21 and may have been cost effective for FY22 at 125% or 150%. The incremental cost per QALY gained for FY21 was substantially lower than for FY22, indicating that testing in care homes was more cost effective prior to vaccination rollout. FY22 aligned with the rollout of vaccination; by April 2022, the start of FY22, 85% of those aged ≥65 years had received their first dose of the vaccine.

Discussion

Our study provides the first large-scale observational evaluation of the impact and cost effectiveness of PCR and LFD testing for COVID-19 in care homes in England. The results suggest that LFD and PCR testing of residents and staff in care homes effectively contained COVID-19 outbreaks and was cost effective for saving the lives of residents. For any future pandemics with similar at-risk populations, it will be essential to rapidly develop reliable diagnostic tests and roll them out to care homes as a priority and to shield particularly vulnerable individuals until these tests become available.

486 Our evaluation of testing implementation found that reported testing intensities responded
487 to some but not all changes in policy over time, although there was considerable
488 heterogeneity among care homes in their responses. Reported testing intensities for LFDs
489 remained consistently below intended levels among staff from October 2020 to March
490 2022, in line with findings from a pilot testing evaluation programme in Liverpool, where
491 just 8·6% and 25·3% of staff achieved >75% and 50% protocol adherence, respectively.[34]
492 Various factors may have contributed to this implementation shortfall, in addition to poor
493 adherence to testing policy among staff.[34] These included issues of test supply during the
494 early stages of the pandemic[35] and under-reporting of implemented tests, especially LFDs,
495 for which reporting was reliant on self-reporting (whereas PCR tests were conducted in and
496 reported by a laboratory). This lack of reporting may have been due to various reasons,
497 including that individuals felt a negative test result was unimportant and therefore they did
498 not report it, while positive test results may not have been reported if people were worried
499 about losing income through not being able to work. Higher reported testing intensities
500 were associated with earlier outbreak discovery and more rapid outbreak control. A similar
501 finding was reported for US nursing homes, with the number of COVID-19 cases per 100
502 potential outbreaks 71·5% (95% CI, 51·6–91·3) lower in high-testing facilities compared with
503 low-testing facilities.[36]

504 An innovation in our study was the decomposition of the process of outbreak mitigation
505 into outbreak discovery and outbreak control; we found certain characteristics of care
506 homes may play different roles in these two processes. Our findings are largely consistent
507 with the literature that does not separate these activities but assesses the correlates of
508 outbreaks in care homes overall. We found that large care homes tended to have smaller
509 outbreaks when they were initially uncovered but that these outbreaks became more
510 difficult to control subsequent to their detection, while a study describing all outbreaks of
511 COVID-19 infection in care homes for older people in Scotland, in March 2020, found that

512 the risk of a COVID-19 outbreak increased with increasing care-home size.[37] Likewise, in our
513 study higher staff-to-resident ratios were associated with larger outbreak sizes when these
514 were uncovered but with more rapid outbreak control afterwards, consistent with both a
515 previous UK report[7] and a study from Ireland.[21] These characteristics of care homes led to
516 an increased likelihood of an outbreak and thus could be used in future to identify those
517 homes requiring a greater focus on testing, although it would remain difficult to control
518 infections throughout an entire care home.

519 In contrast with our findings, an audit found that during the first wave of the COVID-19
520 pandemic (March–June 2020), CQC ratings (different from those we used) were not
521 associated with COVID-19 outbreaks or asymptomatic cases in Liverpool care homes.[23]
522 However, a similar link between the severity of care home outbreaks and care quality
523 standards has been reported for care homes in the US.[38,39]

524 Our results are aligned with those of a population analysis of 189 care homes in the NHS
525 Lothian health region, in Scotland, which estimated that the size of care homes for older
526 people was strongly associated with an increased likelihood of a COVID-19 outbreak (odds
527 ratio per 20-bed increase, 3·35; 95% CI, 1·99–5·63).[1] We found that outbreaks in homes
528 serving older individuals (≥65 years) or those with dementia were controlled more slowly.

529 We identified that testing in care homes was highly cost effective throughout our evaluation
530 period and 3·5-times more cost effective prior to vaccination rollout. Although the rollout of
531 vaccination may have made ongoing testing appear marginally less cost effective, continued
532 testing should be considered a reasonable and overall cost-effective insurance strategy
533 given the uncertainties around the long-term effectiveness of vaccines and the potential for
534 future variants of concern. This also raises the question of whether a standard health
535 economics approach is appropriate for analyses such as this, post-vaccination rollout. In
536 England, testing was continued based on the precautionary principle and because the

537 potential impact of new variants was unknown. Traditional cost-effectiveness analyses do
538 not take into account the willingness to pay for this type of assurance.

539 There are strengths and weaknesses to our study. We had access to large-scale testing data
540 covering all PCR and LFD tests within 14,805 care homes in England reported through the
541 Pillar 2 testing programme between October 2020 and March 2022. Testing data were
542 linked to care home characteristics, test costs, and resident mortality information to
543 contextualise drivers of testing patterns and resident mortality. However, severe COVID-19
544 infection can substantially reduce an individual's quality of life even if it does not lead to
545 death, but due to a lack of hospitalisation data our economic analysis did not include
546 potential cost savings from averted hospitalisations. If these were considered, testing in
547 care homes would likely have emerged as even more cost effective. We found that testing
548 was effective at containing outbreaks in staff, but without staff hospitalisation and deaths
549 data, we could not investigate whether testing could prevent these severe infection
550 outcomes, even though staff in similar settings have been shown to be at high risk of
551 exposure and severe infection [32,35]. Additionally, many wider social benefits have not
552 been included because they are challenging to quantify. These include issues such as the
553 effects of testing on end-of-life quality, the costs of isolation and the resulting mental
554 distress experienced by individuals in care homes due to reduced visitations. In addition,
555 averting hospitalisations will have freed up hospital and staff capacity, enabling better care
556 for emergencies and other diseases. To produce mortality projections, we assumed that the
557 model captured the main causal effect between testing and death after controlling for
558 important confounders, including vaccination status and care home characteristics.
559 However, some of these were inaccurately measured, for example, vaccine coverage for
560 each care home was used as a proxy for immunity to severe COVID-19 infection, but this
561 measure was imprecise as we lacked information about individual residents and staff
562 members in each care home.

This study has implications for the development of testing policies in care homes for future pandemics, particularly for those infectious diseases which have higher morbidity and mortality in older adults or adults with similar characteristics to care home residents. Our analysis found that while testing was a crucial public health intervention in care homes, there were also large heterogeneities across care homes. This raises questions about whether a one-size-fits-all policy for care home testing would be most effective in the event of a future pandemic. However, the impact we have outlined here could not have been achieved through the outbreak management alone that was in place to tackle disease outbreaks in care homes prior to the pandemic. The testing programme was essential in achieving this impact. Furthermore, given that we found testing to remain cost effective even when there were large increases in testing, it may make sense in any future pandemic scenario to rapidly rollout testing across all care homes while simultaneously ramping up this testing for the most at-risk care homes. Post-vaccination rollout, the precautionary principle would suggest that testing be continued. Efforts should be made to evaluate the willingness to pay for this type of assurance.

Contributors

SC, RC, RH, LW, RS, and BL conceived and designed the study. LW, MV, RS, and BL supervised the work. SC, RC, RH, LC, and BL coded the models and analysed the data. SC and MA collected the testing policy data. KS, MV, LW, and BL advised on the methodologies. SC, RC, RH, and BL wrote the initial draft of the manuscript. All authors contributed to guiding the research questions, interpretation of results, and reviewing and approving the manuscript. The data were restricted due to privacy concerns and only available to a subset of the authors. BL directly accessed and verified the underlying data on which this research was based and made the final decision to submit the manuscript. The corresponding and lead authors had full access to all data used in the study.

Data sharing statement

The data supporting the findings of this study are available within the paper and its supplementary materials. The data were made available by UKHSA to the manuscript's authors as part of a retrospective evaluation of England's COVID-19 testing programme. The authors cannot make the underlying datasets publicly available for ethical and legal reasons, particularly given the sensitive nature of the information included. Applications for access to the anonymised data should be submitted to UKHSA.

Ethics statement

The study protocol for the evaluation project, which this research fed into, was granted ethics approval by the UKHSA Research Ethics and Governance Group, reference number NR0347. All relevant ethics guidelines were followed throughout.

Declaration of competing interests

This work was funded by the Secretary of State for Health and Social Care acting as part of the Crown through UKHSA, reference number C80260/PRO5331. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors working for EY and the University of Oxford had financial support from UKHSA for the submitted work; EY LLP London has previously received payment for consultancy and advisory work on the NHS Test & Trace response from the UK Department of Health and Social Care, now known as UKHSA; Susan Hopkins is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (NIHR200915), a partnership between UKHSA and the University of Oxford. The views expressed are those of the authors and not necessarily those of NIHR, UKHSA, or the Department of Health and Social Care. All authors declare no other competing interests.

Acknowledgements

Medical editing support in the preparation of this paper was provided by Adam Bodley, according to Good Publication Practice. The authors would like to express their gratitude to Oliver Munn, Sarah Tunkel, Nick Sharp, Sariyu Shoge, and Olutoye Olatunbosun of UKHSA for sponsoring this research and enabling access to the data used in this study. SH is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (NIHR200915), a partnership between the UK Health Security Agency (UKHSA) and the University of Oxford. The views expressed are those of the author and not necessarily those of the NIHR, UKHSA or the Department of Health and Social Care.

References

1. Burton JK, Bayne G, Evans C, et al. Evolution and effects of COVID-19 outbreaks in care homes: a population analysis in 189 care homes in one geographical region of the UK. *Lancet Healthy Longev* 2020; **1**(1): e21-e31.
2. Alacevich C, Cavalli N, Giuntella O, Lagravinese R, Moscone F, Nicodemo C. The presence of care homes and excess deaths during the COVID-19 pandemic: Evidence from Italy. *Health Econ* 2021; **30**(7): 1703-10.
3. Ballin M, Bergman J, Kivipelto M, Nordström A, Nordström P. Excess Mortality After COVID-19 in Swedish Long-Term Care Facilities. *J Am Med Dir Assoc* 2021; **22**(8): 1574-80.e8.
4. Morciano M, Stokes J, Kontopantelis E, Hall I, Turner AJ. Excess mortality for care home residents during the first 23 weeks of the COVID-19 pandemic in England: a national cohort study. *BMC Med* 2021; **19**(1): 71.
5. Comas-Herrera A, Zalakaín J, Lemmon E, et al. Mortality associated with COVID-19 in care homes: international evidence: International Long Term Care Policy Network, 2021.
6. Hodgson H, Grimm F, Vestesson E, Brine R, Deeny ShdoH--Q. Adult social care and COVID-19: Assessing the impact on social care users and staff in England so far. https://www.health.org.uk/publications/reports/adult-social-care-and-covid-19-assessing-the-impact-on-social-care-users-and-staff-in-england-so-far (accessed 16 April 2024).

641 7. Shallcross L, Burke D, Abbott O, et al. Factors associated with SARS-CoV-2 infection
642 and outbreaks in long-term care facilities in England: a national cross-sectional survey.
643 *Lancet Healthy Longev* 2021; **2**(3): e129-e42.
644 8. Gordon AL, Franklin M, Bradshaw L, Logan P, Elliott R, Gladman JR. Health status of
645 UK care home residents: a cohort study. *Age Ageing* 2014; **43**(1): 97-103.
646 9. Aw D, Woodrow L, Ogliari G, Harwood R. Association of frailty with mortality in older
647 inpatients with Covid-19: a cohort study. *Age Ageing* 2020; **49**(6): 915-22.
648 10. Jeffery-Smith A, Dun-Campbell K, Janarthanan R, et al. Infection and transmission of
649 SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective
650 observational cohort study, England 2020. *Lancet Reg Health Eur* 2021; **3**: 100038.
651 11. EY–Oxford Health Analytics Consortium. Evaluation of the national COVID-19 testing
652 programme in England between October 2020 and March 2022. 2023.
653 https://assets.ey.com/content/dam/ey-sites/ey-com/en_uk/resources/evaluation-of-covid-
654 19-testing-in-england-eoha-conference-edition.pdf (accessed 26 March 2024).
655 12. Department of Health and Social Care. COVID-19: our action plan for adult social
656 care. 2020. https://www.gov.uk/government/publications/coronavirus-covid-19-adult-
657 social-care-action-plan/covid-19-our-action-plan-for-adult-social-care (accessed 19 October
658 2022).
659 13. Department of Health and Social Care. Regular retesting rolled out for care home
660 staff and residents. 2020. https://www.gov.uk/government/news/regular-retesting-rolled-
661 out-for-care-home-staff-and-residents (accessed 29 March 2024).
662 14. Department of Health and Social Care. £149 million to support increased care home
663 testing. 2020. https://www.gov.uk/government/news/149-million-to-support-increased-
664 care-home-testing (accessed 29 March 2024).
665 15. UK Health Security Agency (confidential internal document). Care home staff LFD
666 testing research insights playback February 2021. 2021.
667 16. Hica Group. Coronavirus Update – 16th December 2022. 2022. https://www.hica-
668 uk.com/covid-19-coronavirus/ (accessed 29 March 2024).
669 17. UK Health Security Agency. COVID-19 care home testing guidance for regular and
670 outbreak testing of staff and residents. 2022.
671 https://www.gov.uk/government/publications/coronavirus-covid-19-testing-in-adult-care-
672 homes/covid-19-care-home-testing-guidance-for-regular-and-outbreak-testing-of-staff-and-
673 residents (accessed 29 March 2024).
674 18. Department of Health and Social Care. Changes to coronavirus outbreak testing in
675 care homes (letter). 2021. https://documents.hants.gov.uk/adultservices/Letter-DHSC-
676 Changes-coronavirus-outbreak-testing-care-homes-18-2-21.pdf (accessed 29 March 2024).
677 19. Department of Health & Social Care. Further information on coronavirus testing in
678 care homes (letter). 2020.

https://www.careengland.org.uk/sites/careengland/files/DHSC%20Care%20Home%20Testing%20-%20Letter%2031%20July%202020.pdf (accessed 16 April 2024).
20. Department of Health & Social Care. Care homes: outbreak testing and regular testing (letter). 2020. https://www.careengland.org.uk/sites/careengland/files/Adult%20Social%20Care%20testing%20strategy%20letter%20to%20DPHs%20and%20DASSs%203.7.20.pdf (accessed 16 April 2024).
21. Kennelly SP, Dyer AH, Noonan C, et al. Asymptomatic carriage rates and case fatality of SARS-CoV-2 infection in residents and staff in Irish nursing homes. *Age Ageing* 2020; **50**(1): 49-54.
22. Ladhani SN, Chow JY, Janarthanan R, et al. Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. *EClinicalMedicine* 2020; **26**: 100533.
23. Tulloch JSP, Green R, Tunnah C, Coffey E, Ashton M, Ghebrehewet S. COVID-19 outbreaks in care homes during the first wave: are Care Quality Commission ratings a good predictor of at-risk homes? *J Hosp Infect* 2021; **111**: 96-101.
24. Dutey-Magni PF, Williams H, Jhass A, et al. COVID-19 infection and attributable mortality in UK care homes: cohort study using active surveillance and electronic records (March–June 2020). *Age Ageing* 2021; **50**(4): 1019-28.
25. Naidoo R, Andersen-Waine B, Dahal P, et al. A multistage mixed-methods evaluation of the UKHSA testing response during the COVID-19 pandemic in England (preprint). *medRxiv* 2022: 2022.10.27.22281604.
26. UK Health Security Agency. NHS Test and Trace statistics (England): methodology. 2022. https://www.gov.uk/government/publications/nhs-test-and-trace-statistics-england-methodology/nhs-test-and-trace-statistics-england-methodology (accessed 26 March 2024).
27. NECS. Capacity Tracker. nd. https://www.necsu.nhs.uk/digital-applications/capacity-tracker/ (accessed 26 March 2024).
28. Nicholson G, Lehmann B, Padellini T, et al. Improving local prevalence estimates of SARS-CoV-2 infections using a causal debiasing framework. *Nat Microbiol* 2022; **7**(1): 97-107.
29. Riley S, Atchison C, Ashby D, et al. REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. *Wellcome Open Res* 2020; **5**: 200.
30. Sanger Institute. COVID–19 Genomic Surveillance. nd. https://covid19.sanger.ac.uk/lineages/raw (accessed 26 March 2024).
31. Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020 (accessed 26 March 2024).

32. GOV.UK. The Green Book (2022). 2023. https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-government/the-green-book-2020 (accessed 28 March 2024).
33. National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022. https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation (accessed 28 March 2024).
34. Tulloch JSP, Micocci M, Buckle P, et al. Enhanced lateral flow testing strategies in care homes are associated with poor adherence and were insufficient to prevent COVID-19 outbreaks: results from a mixed methods implementation study. *Age Ageing* 2021; **50**(6): 1868-75.
35. Cracknell J. Fears over Covid-19 test shortage impacting care homes. 2021. https://enfielddispatch.co.uk/fears-over-covid-19-test-shortage-impacting-care-homes/ (accessed 26 March 2024).
36. McGarry BE, Gandhi AD, Barnett ML. Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes. *N Engl J Med* 2023; **388**(12): 1101-10.
37. Burton JK, McMinn M, Vaughan JE, Fleuriot J, Guthrie B. Care-home outbreaks of COVID-19 in Scotland March to May 2020: National linked data cohort analysis. *Age Ageing* 2021; **50**(5): 1482-92.
38. Abrams HR, Loomer L, Gandhi A, Grabowski DC. Characteristics of U.S. Nursing Homes with COVID-19 Cases. *J Am Geriatr Soc* 2020; **68**(8): 1653-6.
39. He M, Li Y, Fang F. Is There a Link between Nursing Home Reported Quality and COVID-19 Cases? Evidence from California Skilled Nursing Facilities. *J Am Med Dir Assoc* 2020; **21**(7): 905-8.

743 **Fig. 1 Characterising the two pathways through which our models assume testing influences outbreak**
744 **dynamics (A and B) and design of positives-to-deaths regression (C)**. Panel (A) shows that higher levels of
745 testing are associated with outbreaks being detected earlier, when they are smaller in size (leading to more
746 rapid outbreak control). Panel (B) shows that higher levels of testing during outbreaks are associated with
747 more rapid control of outbreaks. Panel (C) shows the link between our dependent variable (COVID-19-related
748 deaths) and testing variables, one of our independent variables, in our regressions that focused on COVID-19
749 deaths in individuals who had received a positive test result for COVID-19.



750

751

752

753

754

755

756

757

Fig. 2 Average reported numbers of tests per person per week in England for adult social care staff and residents shown by panel. Blue vertical bars show periods when care homes were closed to visitors (with the exception of visiting for palliative care/end-of-life and named essential caregiver visits) due to government closure policies and community-wide lockdowns.



775 **Fig. 3 Resident COVID-19-related deaths in adult social care homes and model projections under**
776 **hypothetical scenarios.** (A) Confirmed and suspected COVID-19-related deaths of residents in 14,805 English
777 care homes studied. (B) The model-projected total COVID-19-related deaths under hypothetical testing levels
778 relative to historical levels. Each line corresponds to a different counterfactual scenario when the numbers of
779 tests were at the levels shown on the right-hand side of the panel relative to the historical levels, e.g. 50%
780 means that the number of tests was decreased by 50% from its factual level. (C) The model-projected total
781 COVID-19-related deaths under hypothetical care worker levels relative to historical levels. Each line
782 corresponds to a different counterfactual scenario when the numbers of care workers were at the levels
783 shown on the right-hand side of the panel relative to the historical levels, e.g. 125% means that the number of
784 care workers was increased by 25% from its factual level.
785



786

787

788

Fig. 4. Cost effectiveness of actual testing levels in adult social care homes in England compared with various hypothetical levels of testing. The whiskers represent the cost-effectiveness ranges using a minimum QALY of 4.98 per death averted and a maximum of 8.8 per death averted. The points falling below the GBP 70,000 willingness to pay threshold are considered to be cost effective. The points to the right of the vertical lines indicate testing volumes that would be more expensive than the actual strategy was (125%, 150%, and 200% of the actual testing volume).
FY, financial year; QALY, quality-adjusted life-year